C. Valenzuela (Madrid, Spain), S. Tomassetti (Florence, Italy)
GLPG1205 shows reduction in lung volume decline over 26 weeks vs placebo when measured with novel volumetric CT analysis in IPF patients
M. Thillai (Cambridge, United Kingdom), K. Kirov (Cambridge, United Kingdom), E. Santermans (Mechelen, Belgium), M. Roberts (Cambridge, United Kingdom), P. Molyneaux (London, United Kingdom), F. Kanavati (Cambridge, United Kingdom), D. Gallagher (Cambridge, United Kingdom), A. De Haas-Amatsaleh (Mechelen, Belgium), T. Van Der Aa (Mechelen, Belgium), P. Ford (Mechelen, Belgium), C. Seemayer (Basel, Switzerland), B. Van Den Blink (Mechelen, Belgium), A. Ruggiero (Cambridge, United Kingdom)
|   |
GALACTIC-1: Galectin-3 inhibition in idiopathic pulmonary fibrosis (IPF) – rationale, objectives and design of a 52-week, Phase IIb study of GB0139
T. Maher (Los Angeles, United States), M. Wijsenbeek (Rotterdam, Netherlands), N. Hirani (Edinburgh, United Kingdom), B. Lindmark (Copenhagen, Denmark), D. Phung (Copenhagen, Denmark), A. Mac Kinnon (Copenhagen, Denmark), T. Sethi (Copenhagen, Denmark), V. Aslanis (Copenhagen, Denmark), C. Mc Clinton (Copenhagen, Denmark), E. Andersen (Copenhagen, Denmark), H. Schambye (Copenhagen, Denmark), J. Wang-Jairaj (Copenhagen, Denmark)
| |
A phase 2b randomized trial to evaluate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF)
P. Ford (London, United Kingdom), V. Cottin (Lyon, France), K. Flaherty (Ann Arbor, United States), T. Maher (Los Angeles, United States), P. Noble (Los Angeles, United States), M. Wijsenbeek (Rotterdam, Netherlands), M. Chen (Boston, United States), E. Elenko (Boston, United States), L. Micioni (Wall, United States), H. Paden (Woodbury, United States), M. Harnett (Boston, United States), J. Krop (Boston, United States)
| |
Study Design and Rationale for the TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis
S. Nathan (Falls Church, United States), J. Behr (Munich, Germany), V. Cottin (Lyon, France), L. Lancaster (Nashville, United States), P. Smith (RTP, United States), C. Deng (RTP, United States), N. Pearce (RTP, United States), H. Bell (RTP, United States), L. Peterson (RTP, United States), K. Flaherty (Ann Arbor, United States)
| |
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
W. Wuyts (Leuven, Belgium), F. Bonella (Essen, Germany), N. Chaudhuri (Manchester, United Kingdom), F. Varone (Roma, Italy), D. Antin-Ozerkis (New Haven, CT, United States), H. Mueller (Biberach, Germany), C. Coeck (Brussels, Belgium), K. Rohr (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France)
| |
Efficacy of pirfenidone in patients with advanced IPF
J. Behr (Munich, Germany), W. Wuyts (Leuven, Belgium), H. Haller Jr (Louisville, United States), K. Samara (Basel, Switzerland), K. Kirchgässler (Basel, Switzerland), F. Gilberg (Basel, Switzerland), S. Nathan (Falls Church, United States)
| |
Nebulization performance and lung biodistribution profile of PRS-220, an inhaled CTGF antagonist for the treatment of IPF
V. Neiens (Hallbergmoos, Germany), M. Pavlidou (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), T. Jaquin (Hallbergmoos, Germany), E. Hansbauer (Hallbergmoos, Germany), A. Konitsiotis (Hallbergmoos, Germany), J. Morgenstern (Hallbergmoos, Germany), T. Mosebach (Hallbergmoos, Germany), M. Richter (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), M. Hagner (Hallbergmoos, Germany), J. Wrennall (Chapel Hill, United States), R. Tarran (Chapel Hill, United States), G. Matschiner (Hallbergmoos, Germany), S. Olwill (Hallbergmoos, Germany)
| |
Combination antifibrotic therapy in Idiopathic Pulmonary Fibrosis patients: real life experience in an ILD Unit.
E. Martinez Besteiro (Madrid, Spain), M. Beceiro (Madrid, Spain), M. Churruca Arróspide (Madrid, Spain), D. Mouhtar (Madrid, Spain), A. Peláez (Madrid, Spain), T. Alonso (Madrid, Spain), J. Ancochea (Madrid, Spain), C. Valenzuela (Madrid, Spain)
| |
Interstitial lung disease with pulmonary hypertension and the potential for inhaled Treprostinil: A single centre perspective
S. Ramjug (Manchester, United Kingdom), C. Hayton (Manchester, United Kingdom), P. Rivera-Ortega (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), H. Morris (Manchester, United Kingdom), K. Zakis (Manchester, United Kingdom), J. Swale (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), K. Newman (Manchester, United Kingdom), C. Avram (Manchester, United Kingdom), J. Blaikley (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom)
| |
Effects of a twelve-week course of azithromycin on respiratory microbiota in idiopathic pulmonary fibrosis
P. Gijs (Lausanne, Switzerland), C. Daccord (Lausanne, Switzerland), E. Bernasconi (Lausanne, Switzerland), M. Brutsche (St.Gallen, Switzerland), C. Clarenbach (Zurich, Switzerland), S. Guler (Bern, Switzerland), K. Hostettler (Basel, Switzerland), M. Funke-Chambour (Bern, Switzerland), C. Von Garnier (Lausanne, Switzerland)
| |
Drug-drug interactions and safety assessment between selective Prolyl-tRNA Synthetase inhibitor, DWN12088, and “pirfenidone” or “nintedanib” in healthy subjects
M. Park (Seoul, Republic of Korea), J. Kim (Seoul, Republic of Korea), J. Nam (Seoul, Republic of Korea), J. Choi (Seoul, Republic of Korea), W. Shin (Seongnam, Republic of Korea), H. Yoo (Seongnam, Republic of Korea), A. Kim (Seongnam, Republic of Korea)
| |
Comparative analysis of fibroblastic foci in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis
J. Kamp (Hannover, Germany), L. Neubert (Hannover, Germany), H. Stark (Hannover, Germany), J. Hinrichs (Hannover, Germany), C. Boekhoff (Hannover, Germany), A. Seidel (Hannover, Germany), F. Ius (Hannover, Germany), A. Haverich (Hannover, Germany), J. Gottlieb (Hannover, Germany), T. Welte (Hannover, Germany), P. Braubach (Hannover, Germany), F. Laenger (Hannover, Germany), M. Hoeper (Hannover, Germany), M. Kuehnel (Hannover, Germany), D. Jonigk (Hannover, Germany)
| |
INV-101, a cannabinoid receptor-1 inverse agonist, reduces fibrosis in a bleomycin mouse model of IPF
G. Crater (Raleigh, United States), G. Gaucher (Montreal, Canada), M. Harvey (Montreal, Canada), F. Ravenelle (Montreal, Canada)
| |
Changes in Serum Metabolomics in Idiopathic Pulmonary Fibrosis and effect of approved antifibrotic medication
B. Seeliger (Hannover, Germany), A. Carleo (Hannover, Germany), P. Wendel-Garcia (Zurich, Switzerland), J. Fuge (Hannover, Germany), A. Worboys (Barcelona, Spain), S. Schuchardt (Hannover, Germany), M. Molina-Molina (Barcelona, Spain), A. Prasse (Hannover, Germany)
| |
Serum biomarkers of wound healing and basement membrane remodelling are related to disease severity and prognostic for mortality in idiopathic pulmonary fibrosis
P. Juhl (Herlev, Denmark), N. Hoyer (Copenhagen, Denmark), T. Prior (Aarhus, Denmark), P. Frederiksen (Herlev, Denmark), M. Karsdal (Herlev, Denmark), H. Jessen (Herlev, Denmark), D. Leeming (Herlev, Denmark), E. Bendstrup (Aarhus, Denmark), J. Sand (Herlev, Denmark), S. Shaker (Copenhagen, Denmark), P. Juhl (Herlev, Denmark)
| |
Harnessing the therapeutic power of secretomes to treat IPF
M. Timaner (Jerusalem, Israel), T. Fishman-Jacob (Jerusalem, Israel), B. Pertzov (Petah Tikva, Israel), B. Tadmor (Jerusalem, Israel), J. Laufer (Jerusalem, Israel), M. Kramer (Petah Tikva, Israel), Y. Shaked (Haifa, Israel)
| |
Does hypoxia drive alveolar macrophages to potentiate fibrosis in idiopathic pulmonary fibrosis?
L. Davis (Birmingham, United Kingdom), L. Crowley (Birmingham, United Kingdom), E. Jenkins (Birmingham, United Kingdom), D. Parekh (Birmingham, United Kingdom), E. Sapey (Birmingham, United Kingdom), D. Thickett (Birmingham, United Kingdom), A. Scott (Birmingham, United Kingdom)
| |
Late Breaking Abstract - Patients with a genomic classifier result positive for UIP show a greater decline in lung function when treated with combination immunosuppressive therapy
A. Wells (London, United Kingdom), C. Ryerson (Vancouver, Canada), L. Lancaster (Nashville, United States), M. Johnson (South San Francisco, United States), J. Huang (South San Francisco, United States), J. Burbanks-Ivey (South San Francisco, United States), E. Morrie (South San Francisco, United States), L. Lofaro (South San Francisco, United States), W. Bulman (South San Francisco, United States), G. Kennedy (South San Francisco, United States), G. Raghu (Seattle, United States), M. Scholand (Salt Lake City, United States)
| |
Late Breaking Abstract - The effect of antifibrotics in patients with different forms of pulmonary fibrosis: data from the Dutch PF registry
A. van Batenburg (Nieuwegein, Netherlands), G. Nakshbandi (Rotterdam, Netherlands), C. Moor (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands), J. Grutters (Nieuwegein, Netherlands)
| |
Late Breaking Abstract - National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
J. Salonen (Oulu, Finland), M. Purokivi (KuopiKuopio, Finland), U. Hodgson (Helsinki, Finland), R. Kaarteenaho (Oulu, Finland)
| |